Crystalline salts of plasma kallikrein inhibitor patent grant

USPTO issued Patent US12590068B2 to BioCryst Pharmaceuticals, Inc. on March 31, 2026, covering crystalline salt forms of plasma kallikrein inhibitor (Compound I), their preparation methods, and therapeutic applications. The patent application (No. 19313010) was filed August 28, 2025, and contains 30 claims across three CPC classifications related to heterocycles and pharmaceutical formulations.

Patent holders and competitors in the plasma kallikrein inhibitor space should review the patent claims to assess freedom-to-operate considerations. Generic drug manufacturers developing similar kallikrein inhibitors should analyze the crystal form claims before initiating development programs. No immediate compliance actions are required for most organizations; this is a patent grant notification rather than a regulatory requirement.